Uncategorized
Gilead ends a Phase 2/3 trial of long-acting HIV pills
Gilead, one of the few drugmakers in the HIV field, has ended a Phase 2/3 trial of two long-acting HIV pills that had been on hold for safety reasons, Endpoints News has learned.
The California …